Results 21 to 30 of about 3,260 (145)

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia : the ASPEN study [PDF]

, 2020
Se trata de la publicación del estudio de fase 3 ASPEN que comparó en pacientes con macro-globulinemia de Waldenström (WM) la eficacia y la seguridad de ibrutinib, un inhibidor de la tirosi-na quinasa Bruton (BTK) de primera generación, familia que ha ...
Castillo, Jorge J., Wahlin, Björn E, Lee, Hui-Peng, Trotman, Judith, Owen, Roger G, Czyz, Jaroslaw, Motta, Marina, Matous, Jeffrey, Fernández de Larrea, Carlos, de Larrea, Carlos Fernandez, Chan, Wai Y., D'Sa, Shirley, Owen, Roger G., Jurczak, Wojciech, Marlton, Paula Marlton, Garcia Sanz, Ramon, Minnema, Monique C., Tam, Constantine S., Tani, Monica, Trneny, Marek, Chan, Wai Y, Cull, Gavin, Buske, Christian, Cohen, Aileen, Ro, Sunhee, Libby, Edward, Leblond, Veronique, Dimopoulos, Meletios A., Siddiqi, Tanya, Huang, Jane, Matous, Jeffrey V., Opat, Stephen, Marlton, Paula, Mulligan, Stephen, Minnema, Monique C, Wahlin, Björn E., Tam, Constantine, Mccarthy, Helen, Dimopoulos, Meletios, Belada, David, Tedeschi, Alessandra, Schneider, Jingjing, Castillo, Jorge J   +42 more
core   +4 more sources

Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug–Drug Interaction Studies

Drug Design, Development and Therapy
Hailun Xia,1 Yuxin Shen,1,2 Xinhao Xu,1,2 Jun Wu,1,2 Guanyang Lin,1,2 Xiaoxiang Du1 1Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences ...
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X
doaj   +1 more source

Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial [PDF]

Nature Communications
A combination of Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and rituximab has shown promising efficacy in mantle cell lymphoma (MCL). This phase II trial evaluated the second-generation BTK inhibitor zanubrutinib plus rituximab as induction ...
Yuchen Zhang, Man Nie, Yi Cao, Zhiming Li, He Huang, Guowei Li, Xiuhua Sun, Panpan Liu, Yan Gao, Xiaojie Fang, Bing Bai, Jun Cai, Lirong Li, Yingxian Liu, Sihua Peng, Huiqiang Huang, Yi Xia, Qingqing Cai   +17 more
doaj   +2 more sources

Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

CPT: Pharmacometrics & Systems Pharmacology, 2021
A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on the exposures ...
Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C. Ou   +6 more
doaj   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases. [PDF]

MedComm (2020)
BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Sun M, Li D, Wei J.
europepmc   +2 more sources

Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review

Frontiers in Oncology, 2022
Zanubrutinib, a next-generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, shows great efficacy in the treatment of B cell malignancies. Some patients may experience a series of side effects after the treatment of zanubrutinib.
Lingling Wang, Jiao Tang, Jun Feng, Yongfen Huang, Yuexin Cheng, Hao Xu, Yuqing Miao   +6 more
doaj   +1 more source

Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors. [PDF]

Cancer Med
ABSTRACT Background Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized. Methods We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing ...
Schulze FJ, Shumilov E, Behringer A, Kerkhoff A, Eckhardt M, Bätker S, Maulhardt M, Lenz G, Pohlmann A.   +8 more
europepmc   +2 more sources

Bilateral Cystoid Macular Edema with Zanubrutinib Therapy: A Case Report

Case Reports in Oncology, 2023
We present a patient with recurrent mantle cell lymphoma (MCL) who was treated with zanubrutinib, a Bruton’s tyrosine kinase inhibitor. He subsequently developed bilateral cystoid macular edema (CME) in both eyes.
Dante Pennipede, Harrison Sciulli, Radwan Ajlan   +2 more
doaj   +1 more source

Studies of quantum mechanics/molecular docking on zanubrutinib as potential repurposed against Covid-19 [PDF]

, 2022
. Recently, Zanubrutinib, as a novel, selective covalent and potent inhibitor Bruton’s tyrosine kinase (BTK), has been used to treat COVID-19 patients. In this regard, the interaction of Zanubrutinib with Bruton’s tyrosine kinase (BTK) inhibitor studied.
Madadi Mahani , Nosrat, Zia Mohammadi , Sayed   +1 more
core   +1 more source

Table_1_Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.docx

, 2021
Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor. Its safety and effectiveness in central nervous system (CNS) lymphoma along with its distribution in the brain and ability to cross the blood–brain barrier (BBB) remain unknown. This
Daobin Zhou (534876), Danqing Zhao (10645409), Yan Zhang (8098), Wei Zhang (405), Zhe Zhuang (1608523), Wei Wang (17594), Yanan Li (94033), Chong Wei (498649)   +7 more
core   +1 more source